cyn-10 Antibody

Introduction to Cynomolgus-10 Antibody

The term "Cynomolgus-10 Antibody" (often abbreviated as "Cyn-10") refers to antibodies or antibody fragments targeting Cynomolgus monkey (Macaca fascicularis) CXCL10, a chemokine involved in immune responses. These antibodies are engineered to cross-react with human CXCL10 and CXCL9, leveraging structural similarities between species homologs .

CXCL10 (C-X-C motif chemokine ligand 10) and CXCL9 are interferon-gamma-inducible chemokines that bind to the CXCR3 receptor, mediating immune cell migration. Antibodies targeting these chemokines have therapeutic potential in inflammatory and autoimmune diseases .

Key Findings:

• Dual-specific scFvs: Five single-chain variable fragments (scFvs: E7, J9, F13, P8, C1) bind both human and cynomolgus CXCL10/CXCL9 but not CXCL11, despite only 37% sequence identity between CXCL9 and CXCL10 .

• Critical residue: Serine 13 (Ser13) in CXCL9/CXCL10 is essential for antibody binding. This residue is conserved in cynomolgus CXCL10 but absent in CXCL11, explaining selectivity .

• Structural mimicry: The antibodies recognize a conserved surface near the CXCR3 receptor-binding site, enabling cross-reactivity .

Table 1: Species Reactivity of Cyn-10 Antibodies

Mechanistic Insights from Mutagenesis

Site-directed mutagenesis revealed:

1. Ser13 substitution: Replacing Ser13 in human CXCL10 with alanine abolished scFv binding .

2. Glycosaminoglycan (GAG) binding: Cyn-10 antibodies bind CXCL10/CXCL9 immobilized on heparin, suggesting interaction with GAG-associated chemokine conformations .

Comparative Analysis with Other Neutralizing Antibodies

Cyn-10 antibodies share functional parallels with antiviral antibodies, such as:

• Antibody 2G8: Targets Coxsackievirus A10 (CVA10) capsid proteins, demonstrating 100% therapeutic efficacy in murine models .

• Antibody C05: Neutralizes influenza A by inserting a single loop into the hemagglutinin receptor-binding site .

Table 2: Key Features of Neutralizing Antibodies

Applications and Therapeutic Potential

• Inflammatory diseases: Neutralizing CXCL10/CXCL9 may reduce T-cell recruitment in conditions like rheumatoid arthritis .

• Species cross-reactivity: Cynomolgus-reactive antibodies enable preclinical testing in non-human primates .

Limitations and Future Directions

• Affinity challenges: Some scFvs exhibit weak binding to rabbit CXCL10 (e.g., J9) .

• Structural optimization: Improving affinity for cynomolgus CXCL9 could enhance translational utility.